Dr. Reddys Laboratories Ltd.

Dr Reddy’s Laboratories Limited is movingaway from cardiovascular diseases (CVD) and diabetes to focus on new chemicalentities (NCEs) related to unmet needs like anti-infectives for surgicalinfections apart from pain and dermatology for optimising business growth. Thecompany would pursue the existing candidates in the CVD area to their logicalend but it has no new programmes related to both CVD and diabetes partlybecause the costs of clinical trials are too high.  The broad strategy drawn by the company forthe next five years include emerging as one of the top leaders in globalgenerics space in the top five markets, namely India, Russia, US, Germany andUK, be a leading biosimilar player and work on proprietary products. Apart fromthis, Dr Reddy’s would also strive to position itself as a partner of choice inpharmaceutical services and active ingredients segment.

The company would also work towardsrejuvenating the Indian and European markets while continuing to increase itsbusiness in North America. The total pharmaceutical business would be $1.1trillion by 2015 of which 44 per cent would come from the US and Europe,according to the company projections. Though India has been a priority marketfor the company, the growth it has achieved so far has been far below expectations.The company consistently grew more than the industry average in India for 7-8quarters till early 2010. While its new marketing initiatives with regard tobig brands as well as the mass market did work well initially, the results thisyear are way below expectations primarily because of huge attrition among fieldstaff due to aggressive expansion undertaken by MNCs in the country. However,the company expects to see tangible results from these initiatives towards theend of the fourth quarter.